Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-16Clinical Trial Update: Mobile Health (mHealth) App for Safe Opioid Use [NA]
A Rutgers-sponsored clinical trial evaluating a mobile health app for safe opioid use has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-03-09Clinical Trial Update: Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine [Phase 4]
Phase 4 trial comparing intrathecal hydromorphone to intrathecal morphine for post-cesarean pain in patients with opioid use disorder on bup…
-
CLINICAL_TRIALS withdrawal · 2026-02-23Clinical Trial Update: Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder [Phase 2]
A Phase 2 inpatient trial of buprenorphine induction with psilocybin for opioid use disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-18Clinical Trial Update: Combined Injectable Treatment for HIV and OUD [Phase 2]
A Phase 2 trial evaluating a combined injectable treatment for HIV infection and opioid use disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-12-31Clinical Trial Update: Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms [Phase 4]
Phase 4 trial evaluating reduced-dose versus full-dose buprenorphine/naloxone in the perioperative period was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2025-08-14EMA Withdrawn: Sixmo (buprenorphine hydrochloride) — L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.
EMA has withdrawn Sixmo, a buprenorphine hydrochloride injection for opioid use disorder, from the European market. The marketing authorizat…
-
CLINICAL_TRIALS withdrawal · 2025-08-01Clinical Trial Update: A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects [Phase 1]
A Phase 1 study evaluating LUCEMYRA (lofexidine) for opioid withdrawal management in adolescent subjects has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-28Clinical Trial Update: Suboxone Dispenser for OUD [NA]
The clinical trial for a Suboxone dispenser targeting Opioid Use Disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-13Clinical Trial Update: OLP to Manage Pain in TJA: A Feasibility Study [EARLY_Phase 1]
A Phase 1 feasibility trial evaluating OLP for pain management in total joint arthroplasty was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-10Clinical Trial Update: An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder [NA]
This clinical trial update reports that the open-label repetitive transcranial magnetic stimulation study for opioid use disorder has been w…
-
CLINICAL_TRIALS withdrawal · 2025-02-19Clinical Trial Update: HMP for Addictions Study [NA]
The HMP for Addictions study (NCT06063499) sponsored by the University of Wisconsin–Madison has been withdrawn. The trial targeted opioid us…
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: Management of Postoperative Pain After Cesarean Delivery Using Bridge Auricular Percutaneous Nerve Field Stimulator [NA]
The clinical trial assessing Bridge Auricular Percutaneous Nerve Field Stimulator for managing acute postoperative pain after cesarean deliv…
-
CLINICAL_TRIALS withdrawal · 2024-12-20Clinical Trial Update: fNIRs-based Neurofeedback to Reduce Relapse in pOUD/AUD [NA]
A clinical trial evaluating fNIRs-based neurofeedback to reduce relapse in prescription opioid use disorder and alcohol use disorder has bee…
-
CLINICAL_TRIALS withdrawal · 2024-11-12Clinical Trial Update: Feasibility of Pediatric Emergency Department-Initiated Treatment for Adolescents With Opioid Use Disorder [Phase 2]
This update reports that a Phase 2 trial evaluating emergency department-initiated treatment for adolescents with opioid use disorder has be…
-
CLINICAL_TRIALS withdrawal · 2024-11-06Clinical Trial Update: Changing Opioid Users' Negative Attitudes Toward Medication Assisted Treatment [NA]
The clinical trial assessing attitudes toward medication-assisted treatment for opioid use disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-11-06Clinical Trial Update: A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder [Phase 2]
A Phase 2 trial evaluating ASP8062 as an add-on to buprenorphine/naloxone for opioid use disorder has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-07-16Clinical Trial Update: Accelerated Intermittent Theta-Burst Stimulation for Opiate Use Disorder [NA]
The clinical trial NCT03804619 evaluating accelerated intermittent theta-burst stimulation for opioid use disorder has been withdrawn. The s…
-
CLINICAL_TRIALS withdrawal · 2024-05-22Clinical Trial Update: Buprenorphine Induction for Fentanyl Dependent Opioid Users [EARLY_Phase 1]
This early-phase 1 clinical trial evaluating buprenorphine induction for fentanyl-dependent opioid users has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-02-29Clinical Trial Update: Assessing Optimal XR-Buprenorphine Initiation Points in Jail [Phase 4]
Clinical trial investigating initiation points for XR-Buprenorphine in jail for opioid use disorder was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-06-18Clinical Trial Update: Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder [Phase 4]
Phase 4 trial investigating anti-suicidal effects of buprenorphine in opioid use disorder was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2021-02-12Clinical Trial Update: Virginia Opioid Treatment-Emergency Department [Phase 3]
A Phase 3 clinical trial for opioid use disorder conducted by Virginia Commonwealth University has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-10-14Clinical Trial Update: Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women [Phase 4]
Phase 4 trial comparing long-acting subcutaneous buprenorphine to short-acting sublingual buprenorphine in pregnant and lactating women with…
-
CLINICAL_TRIALS withdrawal · 2020-10-08Clinical Trial Update: An Open-Label, Single-Center Study to Evaluate the Exposure-Response Relationship Between the Plasma Drug Concentrations and the Change From Baseline in QTc at Steady State Following Once-daily Administration of CASSIPA® in Opioid Dependent Subjects. [Phase 4]
An open-label Phase 4 trial evaluating exposure–response for QTc changes with once-daily CASSIPA in opioid-dependent subjects was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-03-24Clinical Trial Update: Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology [Phase 4]
A Phase 4 trial comparing buprenorphine alone versus buprenorphine with naloxone for maternal symptomatology in opioid-use disorder was with…
-
CLINICAL_TRIALS withdrawal · 2017-07-24Clinical Trial Update: The Mobile Monitoring of Vital Signs in Opioid Users [NA]
A clinical trial (NCT02647073) evaluating mobile monitoring of vital signs in individuals with opioid use disorder has been withdrawn.